Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
NCT03167385Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in differentiated thyroid carcinoma (DTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease Control Rate at 2 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT03167385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167385.